About: http://data.cimple.eu/news-article/3730431bb95302c9793a166359174ebbaf292b8fe0b81fc397db7d9e

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/3730431bb95302c9793a166359174ebbaf292b8fe0b81fc397db7d9e Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	South Africa is unlikely to reach its 2021 coronavirus herd immunity target and should "recalibrate" expectations around Covid-19 jabs, a top vaccinologist said Monday. A more transmissible coronavirus variant first identified in South Africa late last year fuelled the country's second infection wave and delayed the start of vaccinations in February. Studies have shown the variant to be more resistant to most of the existing vaccines than the virus' original form and other mutations. Vaccinology professor Shabir Madhi, lead investigator on the Oxford/AstraZeneca vaccine trial in South Africa, said the local variant and a third wave of infections expected later this year were likely to hinder inoculation plans. "We need to recalibrate... our understanding of what we can actually achieve with Covid-19 vaccines," Madhi told a virtual panel discussion. "The notion of getting to herd immunity... at least with this first generation of Covid-19 vaccines, is extremely slim." South Africa's government aims to vaccinate 67 percent of its population -- around 40 million people -- to achieve herd immunity by year's end. Inoculations started last month with jabs developed by US pharma giant Johnson & Johnson. The rollout was briefly delayed after a study found that AstraZeneca vaccines -- the first doses to land in the country -- only offered limited protection against mild and moderate disease caused by the new variant. Substantial quantities of the vaccines are only expected in April and May. Infections are meanwhile expected to resurge in June or earlier if a cap on mass gatherings is lifted during the upcoming Easter holiday. So far South Africa has secured 11 million Johnson & Johnson vaccines and 20 million doses of a jab developed by Pfizer. Another 12 million doses are expected from the WHO-backed vaccine pooling initiative Covax and an undetermined amount from the African Union. The country is the worst-hit by the pandemic in Africa, with over 1.5 million cases and almost 50,000 deaths recorded to date. But President Cyril Ramaphosa on Sunday said the start of vaccinations had "gone extremely well" and that daily infections had slowed enough to lift almost all movement restrictions. sch/ho/sn/tgb
schema:headline	S.Africa likely to miss herd immunity target : scientist
schema:mentions	Smart Lander for Investigating Moon Hinder Inoculation Herd immunity Cyril Ramaphosa Johnson & Johnson Easter Jab University of Oxford Africa AstraZeneca South Africa Pandemic Virus Pfizer Vaccine United States Coronavirus President of the United States Coronavirus disease 2019 Five-prime cap Shabir
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2021-03-01 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	positive sentiment
http://data.cimple...readability_score	75 (xsd:integer)
http://data.cimple...tology#hasEmotion	fear

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 11 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software